

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Pulmonary disease				
Pulmonary fibrosis	IL-17 (IL-17A)	<p>A study in patient samples and in mice suggests that inhibiting IL-17A could help treat idiopathic pulmonary fibrosis (IPF). In mouse models of bleomycin-induced and IL-1β-induced pulmonary fibrosis, <i>Il-17a</i> knockout reduced disease severity compared with that in wild-type controls. Samples from IPF patients had higher levels of IL-17A than samples from healthy volunteers. Next steps could include finding patient subsets that overexpress IL-17A and generating a mAb against IL-17A or its receptors.</p> <p>SciBX 3(9); doi:10.1038/scibx.2010.287 Published online March 4, 2010</p>	Work unpatented; unavailable for licensing	<p>Wilson, M. <i>et al. J. Exp. Med.</i>; published online Feb. 22, 2010; doi:10.1084/jem.20092121</p> <p>Contact: Thomas A. Wynn, National Institutes of Health, Bethesda, Md. e-mail: twynn@niaid.nih.gov</p>